510(k) device
Vrnt
Cognifisense, Inc. · Virtual Reality Behavioral Therapy Device For Pain Relief (QRA, Class II) · First FDA decision Oct 31, 2023, newest Apr 10, 2026Chronic pain
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
2
Naming "Vrnt"
MAUDE reports
0
Brand "Vrnt", since 2015
PubMed studies
14
Mentioning "Vrnt"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Vrnt
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- VRNT510(k)
K254004 · Decided Apr 10, 2026 · 116 days after receipt
Device type: Virtual Reality Behavioral Therapy Device For Pain Relief (QRA) · Neurology & Neurosurgery
- VRNT510(k)
K230814 · Decided Oct 31, 2023 · 221 days after receipt
Device type: Virtual Reality Behavioral Therapy Device For Pain Relief (QRA) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Intensive Behavioral Therapy for ObesityNational analysisReview closedCAG-00423NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational analysisReview closedCAG-00424NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for ObesityNational determinationOn the books210.12Updated Dec 2, 2024
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational determinationOn the books210.11Updated Dec 2, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Vrnt", any status and sponsor, newest update first.
- Virtual Reality Treatment for Adults With Chronic Back Pain (VRNT)Pivotal-lookingActive, not recruiting
CognifiSense Inc.Not on our public-company list
NCT07033195 · 200 participants (planned) · Start Jun 1, 2025 · Primary completion Feb 20, 2027
Device: Skills-based Virtual Reality Therapy; Distraction-based Virtual Reality Therapy · For: Chronic Pain; Chronic Back Pain; Chronic Lower Back Pain (CLBP)
Sites: Boulder, Colorado
CognifiSense Inc.Not on our public-company list
NCT04468074 · 72 participants · Start Jun 9, 2020 · Primary completion Apr 13, 2021
Device: Virtual Reality Therapy for Chronic Pain · For: Chronic Pain; Back Pain Lower Back Chronic; Back Pain
Sites: Boulder, Colorado
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Vrnt", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QRA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Vrnt"[tiab]. The summary above synthesizes these.
- The effects of virtual reality neuroscience-based therapy on clinical and neuroimaging outcomes in patients with chronic back pain: a randomized clinical trial.
Čeko M, Baeuerle T, Webster L, et al. · Pain · 2024Randomized Controlled Trial
- Virus reduction neutralization test and LI-COR microneutralization assay bridging and WHO international standard calibration studies for respiratory syncytial virus.
Sun D, Homan YX, Antonello JM, et al. · Bioanalysis · 2022
- Clinical test for Attention Enhancement System.
Cho BH, Ku J, Jang D, et al. · Stud Health Technol Inform · 2002Clinical Trial, Comparative Study
- A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.
Russell KL, Rupp RE, Morales-Ramirez JO, et al. · Hum Vaccin Immunother · 2022Clinical Trial, Phase I, Randomized Controlled Trial
- The Effects of Virtual Reality Neuroscience-based Therapy on Clinical and Neuroimaging Outcomes in Patients with Chronic Back Pain: A Randomized Clinical Trial.
Čeko M, Baeuerle T, Webster L, et al. · medRxiv · 2023Preprint
- Virus Reduction Neutralization Test: A Single-Cell Imaging High-Throughput Virus Neutralization Assay for Dengue.
Whiteman MC, Bogardus L, Giacone DG, et al. · Am J Trop Med Hyg · 2018
- Development and qualification of a fast, high-throughput and robust imaging-based neutralization assay for respiratory syncytial virus.
Sun D, Hsu A, Bogardus L, et al. · J Immunol Methods · 2021Comparative Study
- Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine.
Peixoto de Miranda ÉJF, de Sousa Moreira JA, da Silva Braga R, et al. · Vaccine · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Using virtual reality to distinguish subjects with multiple- but not single-domain amnestic mild cognitive impairment from normal elderly subjects.
Mohammadi A, Kargar M, Hesami E · Psychogeriatrics · 2018
- Effectiveness of the Use of Virtual Reality Rehabilitation in Children with Dyslexia: Follow-Up after One Year.
Maresca G, Corallo F, De Cola MC, et al. · Brain Sci · 2024
- Detecting allocentric and egocentric navigation deficits in patients with schizophrenia and bipolar disorder using virtual reality.
Mohammadi A, Hesami E, Kargar M, et al. · Neuropsychol Rehabil · 2018
- Differential diagnosis of schizophrenia and schizoaffective disorder from normal subjects using virtual reality.
Kargar M, Askari S, Khoshaman A, et al. · Psychiatry Res · 2019
Other devices of this type
Also filed under product code QRA.
- RelieVRx (Pico G3)Appliedvr · 510(k) 2025
- Smileyscope System (Therapy Mode)Smileyscope Holding, Inc. · 510(k) 2023
- EaseVRxAppliedvr, Inc. · De Novo 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.